3SBio Inc - Asset Resilience Ratio

Latest as of December 2025: 10.64%

3SBio Inc (83B) has an Asset Resilience Ratio of 10.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of 3SBio Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€3.86 Billion
≈ $4.51 Billion USD Cash + Short-term Investments

Total Assets

€36.25 Billion
≈ $42.38 Billion USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how 3SBio Inc's Asset Resilience Ratio has changed over time. See 3SBio Inc net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down 3SBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of 3SBio Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €3.86 Billion 10.64%
Total Liquid Assets €3.86 Billion 10.64%

Asset Resilience Insights

  • Moderate Liquidity: 3SBio Inc has 10.64% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

3SBio Inc Industry Peers by Asset Resilience Ratio

Compare 3SBio Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
SillaJen Inc
KQ:215600
Biotechnology 50.41%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Abivax SA
PA:ABVX
Biotechnology 2.34%
ABL Bio Inc
KQ:298380
Biotechnology 0.69%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%

Annual Asset Resilience Ratio for 3SBio Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for 3SBio Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.64% €3.86 Billion
≈ $4.51 Billion
€36.25 Billion
≈ $42.38 Billion
-4.93pp
2024-12-31 15.57% €3.77 Billion
≈ $4.41 Billion
€24.21 Billion
≈ $28.31 Billion
+1.59pp
2023-12-31 13.98% €3.30 Billion
≈ $3.86 Billion
€23.63 Billion
≈ $27.62 Billion
-8.13pp
2022-12-31 22.11% €4.86 Billion
≈ $5.68 Billion
€21.99 Billion
≈ $25.71 Billion
+12.22pp
2021-12-31 9.89% €1.90 Billion
≈ $2.22 Billion
€19.21 Billion
≈ $22.46 Billion
+2.69pp
2020-12-31 7.20% €1.27 Billion
≈ $1.49 Billion
€17.68 Billion
≈ $20.67 Billion
+4.01pp
2019-12-31 3.19% €472.16 Million
≈ $552.01 Million
€14.81 Billion
≈ $17.31 Billion
+2.70pp
2018-12-31 0.49% €68.13 Million
≈ $79.65 Million
€13.84 Billion
≈ $16.18 Billion
-4.63pp
2017-12-31 5.12% €704.56 Million
≈ $823.71 Million
€13.75 Billion
≈ $16.08 Billion
+1.84pp
2016-12-31 3.28% €362.17 Million
≈ $423.42 Million
€11.04 Billion
≈ $12.91 Billion
--
pp = percentage points

About 3SBio Inc

F:83B Germany Biotechnology
Market Cap
$5.15 Billion
€4.40 Billion EUR
Market Cap Rank
#3531 Global
#646 in Germany
Share Price
€1.76
Change (1 day)
-2.07%
52-Week Range
€1.63 - €3.88
All Time High
€3.88
About

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more